Bevacizumab is the only therapeutic target approved for patients with persistent, recurrent or advanced cervical cancer from a phase III study that combined with chemotherapy; it proves a significant increase in overall survival.
Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating Keytruda, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) met its primary endpoint of overall survival (OS) for the treatment of newly diagnosed patients with high-risk locally advanced cervical cancer.
Genentech/Roche has announced that the FDA approved Avastin (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for...
Celltrion USA announced that the FDA has approved Vegzelma (bevacizumab-adcd), a biosimilar to Avastin (bevacizumab), for the treatment of six types of cancer: metastatic colorectal cancer; recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC); recurrent glioblastoma; metastatic renal cell carcinoma; persistent, recurrent, or metastatic cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The European Commission (EU) approved Avastin (bevacizumab), from Roche, in combination with standard chemotherapy (paclitaxel and cisplatin or, alternatively, paclitaxel...
The European Union’s Committee for Medicinal Products for Human Use has issued a positive opinion on the use of Avastin...
Merck Inc., announced that Keytruda, Merck’s anti-PD-1 therapy, received four new approvals from Japan’s Ministry of Health, Labor and Welfare (MHLW) including: Keytruda approved in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with advanced or recurrent cervical cancer with no prior chemotherapy who are not amenable to curative treatment, based on data from the KEYNOTE-826 trial
Celltrion Healthcare announced that the European Commission (EC) has approved Vegzelma (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer.
Merck Inc announced that the European Commission has approved Keytruda (pembrolizumab) in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in adults whose tumors express PD-L1 (Combined Positive Score [CPS] at least 1).
Pfizer announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a...